[1]

Altekruse SF, Jane Henley S, Cucinelli JE, McGlynn KA. 2014. Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. The American Journal of Gastroenterology 109:542−53

doi: 10.1038/ajg.2014.11
[2]

Anwanwan D, Singh SK, Singh S, Saikam V, Singh R. 2020. Challenges in liver cancer and possible treatment approaches. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1873:188314

doi: 10.1016/j.bbcan.2019.188314
[3]

Barry KC, Hsu J, Broz ML, Cueto FJ, Binnewies M, et al. 2018. A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nature Medicine 24:1178−91

doi: 10.1038/s41591-018-0085-8
[4]

Böttcher JP, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrerizo M, et al. 2018. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell 172:1022−1037.e14

doi: 10.1016/j.cell.2018.01.004
[5]

Böttcher JP, Reis e Sousa C. 2018. The role of type 1 conventional dendritic cells in cancer immunity. Trends in Cancer 4(11):784−92

doi: 10.1016/j.trecan.2018.09.001
[6]

Bowden J, Holmes MV. 2019. Meta-analysis and mendelian randomization: a review. Research Synthesis Methods 10(4):486−96

doi: 10.1002/jrsm.1346
[7]

Freddie Bray BSc M, MSc ML, PhD HS, Me JF, et al. 2024. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 74(3):229−63

doi: 10.3322/caac.21834
[8]

Chen DS, Mellman I. 2013. Oncology meets immunology: the cancer-immunity cycle. Immunity 39(1):1−10

doi: 10.1016/j.immuni.2013.07.012
[9]

Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, et al. 2009. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. The Lancet Oncology 10(1):25−34

doi: 10.1016/S1470-2045(08)70285-7
[10]

Chew V, Lai L, Pan L, Lim CJ, Li J, et al. 2017. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses. Proceedings of the National Academy of Sciences of the United States of America 114(29):E5900−E5909

doi: 10.1073/pnas.1706559114
[11]

Corrales L, Glickman LH, McWhirter SM, Kanne DB, Sivick KE, et al. 2015. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Reports 11(7):1018−30

doi: 10.1016/j.celrep.2015.04.031
[12]

Iñarrairaegui M, Melero I, Sangro B. 2018. Immunotherapy of hepatocellular carcinoma: facts and hopes. Clinical Cancer Research 24(7):1518−24

doi: 10.1158/1078-0432.CCR-17-0289
[13]

Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, et al. 2016. Hepatocellular carcinoma. Nature Reviews Disease Primers 2:16018

doi: 10.1038/nrdp.2016.18
[14]

Mizukoshi E, Kaneko S. 2019. Immune cell therapy for hepatocellular carcinoma. Journal of Hematology & Oncology 12:52

doi: 10.1186/s13045-019-0742-5
[15]

Peng W, Chen JQ, Liu C, Malu S, Creasy C, et al. 2016. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discovery 6(2):202−16

doi: 10.1158/2159-8290.CD-15-0283
[16]

Spranger S, Gajewski TF. 2018. Impact of oncogenic pathways on evasion of antitumour immune responses. Nature Reviews Cancer 18(3):139−47

doi: 10.1038/nrc.2017.117
[17]

Xu L, Kim Y, Spolverato G, Gani F, Pawlik TM. 2016. Racial disparities in treatment and survival of patients with hepatocellular carcinoma in the United States. Hepatobiliary Surgery and Nutrition 5(1):43−52

doi: 10.3978/j.issn.2304-3881.2015.08.05
[18]

Bergantini L, D’Alessandro M, Cameli P, Vietri L, Vagaggini C, et al. 2020. Effects of rituximab therapy on B cell differentiation and depletion. Clinical Rheumatology 39(5):1415−21

doi: 10.1007/s10067-020-04996-7
[19]

Bouras E, Karhunen V, Gill D, Huang J, Haycock PC, et al. 2022. Circulating inflammatory cytokines and risk of five cancers: a Mendelian randomization analysis. BMC Medicine 20:3

doi: 10.1186/s12916-021-02193-0
[20]

Chen Z, Zhang G, Ren X, Yao Z, Zhou Q, et al. 2023. Cross-talk between myeloid and B cells shapes the distinct microenvironments of primary and secondary liver cancer. Cancer Research 83(21):3544−61

doi: 10.1158/0008-5472.CAN-23-0193
[21]

Garnelo M, Tan A, Her Z, Yeong J, Lim CJ, et al. 2017. Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma. Gut 66(2):342−51

doi: 10.1136/gutjnl-2015-310814
[22]

Gu J, Yan GM, Kong XL, Zhang YY, Huang LH, et al. 2023. Assessing the causal relationship between immune traits and systemic lupus erythematosus by bi-directional Mendelian randomization analysis. Molecular Genetics and Genomics 298(6):1493−503

doi: 10.1007/s00438-023-02071-9
[23]

Hardy RR, Hayakawa K. 2001. B cell development pathways. Annual Review of Immunology 19:595−621

doi: 10.1146/annurev.immunol.19.1.595
[24]

Fei Y, Yu H, Wu Y, Gong S. 2024. The causal relationship between immune cells and ankylosing spondylitis: a bidirectional Mendelian randomization study. Arthritis Research & Therapy 26:24

doi: 10.1186/s13075-024-03266-0
[25]

Ma J, Wu Y, Ma L, Yang X, Zhang T, et al. 2024. A blueprint for tumor-infiltrating B cells across human cancers. Science 384:eadj4857

doi: 10.1126/science.adj4857
[26]

Shalapour S, Lin XJ, Bastian IN, Brain J, Burt AD, et al. 2017. Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. Nature 551:340−45

doi: 10.1038/nature24302
[27]

He D, Liu L, Shen D, Zou P, Cui L. 2022. The effect of peripheral immune cell counts on the risk of multiple sclerosis: a mendelian randomization study. Frontiers in Immunology 13:867693

doi: 10.3389/fimmu.2022.867693
[28]

Wang C, Zhu D, Zhang D, Zuo X, Yao L, et al. 2023. Causal role of immune cells in schizophrenia: Mendelian randomization (MR) study. BMC Psychiatry 23:590

doi: 10.1186/s12888-023-05081-4